SPECIAL NOTICE
A -- TECHNOLOGY/BUSINESS OPPORTUNITY Rapid, Easy-to-Use Detection of Respiratory Pathogens in Emergency Rooms
- Notice Date
- 7/20/2006
- Notice Type
- Special Notice
- NAICS
- 238990
— All Other Specialty Trade Contractors
- Contracting Office
- Department of Energy, Lawrence Livermore National Laboratory (DOE Contractor), Industrial Partnerships & Commercialization, 7000 East Avenue L-795, Livermore, CA, 94550
- ZIP Code
- 94550
- Solicitation Number
- Reference-Number-FBO135-06
- Response Due
- 8/21/2006
- Archive Date
- 8/22/2006
- Description
- TECHNOLOGY/BUSINESS OPPORTUNITY Rapid, Easy-to-Use Detection of Respiratory Pathogens in Emergency Rooms Opportunity: Lawrence Livermore National Laboratory (LLNL), operated by the University of California under contract with the U.S. Department of Energy (DOE), is offering the opportunity to license an instrument for rapid, point-of-care pathogen detection. Background: Patients with ?flu-like?symptoms usually wait long hours in emergency rooms (ER) due to lack of rapid diagnostic capability. Current methods take about two weeks for results to come back, thereby forcing the ER physician to make an ?educated guess? based on available clinical data. ?Diagnosis? generally results in costly hospital stays, improper use of antibiotics, and heavy burdens on the med-tech labs. Description: This technology gives ER health care providers the capability to diagnose patients with ?flu-like? symptoms within 2-3 hours. From a nasal swab sample from the patient, the automated platform handles sample movement, amplification, hybridization, and data analysis. Called FluIDx, this diagnostic instrument is being developed for use in hospitals & clinics. Advantages: Rapid diagnosis  perfect for emergency situations  may reduce length of hospital stays, antibiotic use, lab work  lower medical costs for the patient Small, Cost-Effective, and Easy-to-Use  lower operating costs Multiplexed  Simultaneous detection of multiple agents from a single sample  higher productivity Can easily incorporate other pathogen assays  higher flexibility and adaptability Potential Applications: Although the FluIDx instrument is designed to detect respiratory pathogens in emergency rooms, the technology can be used in any situation where biological assays (enzyme, nucleic acid, protein, etc.) are used. Biomedical screening and diagnostic applications Bioforensics Drug discovery Proteomics If reduced to a field portable unit, First Responders Intellectual Property: U.S. patent applications have been filed for both the platform and the assays. Development Status: Two prototypes of the FluIDx instrument have been developed, one of which is being used in the Emergency Room at the UC Davis Medical Center in Sacramento, California. To view a picture of the prototype go to: http://www.llnl.gov/IPandC/technology/profile/announcement/Pathogen-Detection.php LLNL is seeking industry partners with a demonstrated ability to bring such inventions to the market. Moving critical technology beyond the Laboratory to the commercial world helps our licensees gain a competitive edge in the marketplace. All licensing activities are conducted under policies relating to the strict nondisclosure of company proprietary information. Please visit the IPAC website at http://www.llnl.gov/IPandC/workwithus/partneringprocess.php for more information on working with LLNL and the industrial partnering and technology transfer process. Note: THIS IS NOT A PROCUREMENT. Companies interested in commercializing LLNL's FluIDx technology should provide a written statement of interest, which includes the following: 1. Company Name and address. 2. The name, address, and telephone number of a point of contact. 3. A description of corporate expertise and facilities relevant to commercializing this technology. Written responses should be directed to: Lawrence Livermore National Laboratory Industrial Partnerships and Commercialization P.O. Box 808, L-795 Livermore, CA 94551-0808 Attention: FBO 135-06 Please provide your written statement within thirty (30) days from the date this announcement is published to ensure consideration of your interest in LLNL's FluIDx technology.
- Record
- SN01093672-W 20060722/060720220514 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |